Welcome to the Bladder Cancer website! Please take a look around at the content of the journal and other features of this community portal, including joining the discussion thread about the latest challenging cases, or taking a look at the funding analyzer.

The authors conducted a systematic review of the literature on oredictive molecular biomarkers associated with response to PD-1 and PD-L1 inhibitors. The visual illustrates the immune checkpoint blockade in advanced bladder cancer ranking the predictive value, with biomarkers closer to the center being more predictive of response. From: Tu, et al., Bladder Cancer, vol. 5, no. 2, pp. 131–145, 2019

Clinical development of fibroblast growth factor receptor 3 (FGFR3) inhibitors for the treatment of urothelial cancer. The visual illustrates the dimerization of FGFR leads to the phosphorylation of the intracellular tyrosine kinase domains which results in the activation of a cascade of downstream events including the mitogen-activated protein kinase, the signal transducer and activator of transcription, the phosphoinositide-3-kinase/Akt, the nuclear factor-kappa B, and the PLC-gamma pathways resulting in DNA transcription. From: Ibrahim, et al., Bladder Cancer, vol. 5, no. 2, pp. 87–102, 2019

This study aims to learn about patients’ experiences with treatment choice, surgical care, and recovery across health settings. Understanding patient experiences is essential to closing care gaps and developing patient-reported measures. From: McMullen, et al., Bladder Cancer, vol. 5, no. 1, pp. 51–61, 2019

This study provides an overview and resources on the origin, pathological and molecular characteristics of commonly used human, murine and canine BC cell lines. The Venn diagram illustrates the 127 human bladder cancer cell lines analyzed in five panels. From: TCM Zuiverloon et al., Bladder Cancer, vol. 4, no. 2, pp. 169–183, 2018

The synergistic relationship between immunotherapy and radiation. From Buchwald and Efstathiou. Bladder Cancer, vol. 1, no. 1, pp. 15–27, 2016

We are pleased to announce that, as of 2018, Bladder Cancer is classified as the official journal of the Bladder Cancer Advocacy Network (BCAN). Read more about this new partnership to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities via the following link: http://tiny.cc/BLC-BCAN_PR